← BIOMARIN PHARMACEUTICAL INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $408.3m | $598.0m | $494.0m | $437.4m | $649.2m | $587.3m | $724.5m | $755.1m | $942.8m | $1.3b | |
| Short-term Investments | $381.3m | $797.9m | $590.3m | $316.4m | $416.2m | $426.6m | $567.0m | $318.7m | $194.9m | $248.9m | |
| Inventory, Net | $355.1m | $475.8m | $530.9m | $680.3m | $698.5m | $776.7m | $894.1m | $1.1b | $1.2b | $1.3b | |
| Assets, Current | $1.4b | $2.2b | $2.1b | $1.9b | $2.3b | $2.3b | $2.8b | $3.0b | $3.2b | $4.0b | |
| Property, Plant and Equipment, Net | $798.8m | $896.7m | $948.7m | $1.0b | $1.0b | $1.0b | $1.1b | $1.1b | $1.0b | $952.5m | |
| Goodwill | $197.0m | $197.0m | $197.0m | $197.0m | $196.2m | $196.2m | $196.2m | $196.2m | $196.2m | $196.2m | |
| Intangible Assets, Net (Excluding Goodwill) | $553.8m | $517.5m | $491.8m | $456.6m | $417.3m | $388.7m | $338.6m | $294.7m | $255.3m | $213.8m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $49.0m | $46.0m | $38.2m | $34.9m | $42.7m | $28.7m | $35.2m | |
| Other Assets, Noncurrent | $32.8m | $29.9m | $36.6m | $122.0m | $142.2m | $151.8m | $176.2m | $171.5m | $251.4m | $277.0m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $215.3m | $261.4m | $342.6m | $377.4m | $448.4m | $373.4m | $461.3m | $633.7m | $660.5m | $908.2m | |
| Assets | $4.0b | $4.6b | $4.4b | $4.7b | $5.8b | $6.0b | $6.4b | $6.8b | $7.0b | $7.6b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $7.5m | $8.9m | $8.2m | $8.1m | $8.6m | $7.2m | $8.6m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $44.1m | $40.5m | $31.9m | $26.3m | $38.0m | $30.5m | $36.6m | |
| Liabilities, Current | $439.3m | $816.5m | $523.2m | $932.5m | $492.5m | $539.8m | $588.9m | $1.2b | $607.0m | $759.0m | |
| Other Liabilities, Noncurrent | $42.0m | $59.1m | $58.6m | $98.1m | $114.2m | $98.5m | $100.0m | $119.9m | $128.8m | $150.8m | |
| Deferred Tax Liabilities, Net | $56.9m | $44.3m | $62.1m | $64.9m | $67.0m | $64.2m | $66.1m | $69.2m | $62.6m | $33.3m | |
| Liabilities | $1.3b | $1.8b | $1.5b | $1.6b | $1.7b | $1.7b | $1.8b | $1.9b | $1.3b | $1.5b | |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, Issued | $173k | $176k | $178k | $180k | $182k | $184k | $186k | $189k | $191k | $192k | |
| Retained Earnings (Accumulated Deficit) | ($1.5b) | ($1.6b) | ($1.7b) | ($1.7b) | ($861.6m) | ($925.7m) | ($789.2m) | ($621.6m) | ($194.7m) | $154.2m | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $12.8m | ($23.0m) | $5.3m | $20.2m | ($16.1m) | $14.4m | ($3.9m) | ($28.8m) | $61.7m | ($13.5m) | |
| Additional Paid in Capital, Common Stock | $4.3b | $4.5b | $4.7b | $4.8b | $5.0b | $5.2b | $5.4b | $5.6b | $5.8b | $6.0b | |
| Stockholders' Equity Attributable to Parent | $2.8b | $2.8b | $3.0b | $3.1b | $4.1b | $4.3b | $4.6b | $5.0b | $5.7b | $6.1b | |
| Liabilities and Equity | $4.0b | $4.6b | $4.4b | $4.7b | $5.8b | $6.0b | $6.4b | $6.8b | $7.0b | $7.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.